Evaluation of the Renal Congestion, Perfusion and Function Before and After Diuretic Treatment in the ICU

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03704844

Acronym

ECHOFURO

Enrollment

120

Registered

2018-10-15

Start date

2018-12-01

Completion date

2021-12-31

Last updated

2019-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Congestion

Brief summary

Renal congestion is a pathological state that can lead to acute kidney failure. Furosemide is known to lower renal congestion by its diuretic effect. The aim of this trial is to study the reversibility of kidney congestion under diuretic therapy and assess through echodoppler parameters if it can improve renal perfusion and function in congestive ICU patients. It could in fine lead to a better identification of patients that could benefit from diuretic therapy in the ICU.

Interventions

OTHERnon applicable

non applicable

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient hospitalized in ICU * under furosemide treatment

Exclusion criteria

* participation refusal * uncontrolled shock (MAP\<65mmHg) * abdominal compartment syndrome * diuretic administration in the 6 hours prior to inclusion * renal replacement therapy or stage 4-5 chronic kidney disease * atrial fibrillation * no monitoring of CVP / invasive arterial pressure

Design outcomes

Primary

Measure	Time frame	Description
Effects of diuretics	24 hours	Evaluation of renal perfusion diuretic treatment by measuring the renal resistance index and the renal venous impedance index.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026